1α,25-二羟维生素 D3-3β-溴代醋酸酯，一种有潜力的癌症治疗药物：合成与作用机制。
1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.
机构信息
Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
出版信息
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2537-40. doi: 10.1016/j.bmcl.2011.02.025. Epub 2011 Feb 18.
Abstract
Synthesis of 1α,25-dihydroxyvitamin D(3)-3β-bromoacetate (1,25(OH)(2)D(3)-3-BE), a potential anti-cancer agent is presented. We also report that mechanism of action of 1,25(OH)(2)D(3)-3-BE may involve reduction of its catabolism, as evidenced by the reduced and delayed expression of 1α,25-dihydroxyvitamin D(3)-24-hydroxylase (CYP24) gene in cellular assays.
摘要
1α,25-二羟维生素 D(3)-3β-溴乙酸酯（1,25(OH)(2)D(3)-3-BE）的合成，一种潜在的抗癌剂，被呈现出来。我们还报告说，1,25(OH)(2)D(3)-3-BE 的作用机制可能涉及减少其分解代谢，这可以从细胞测定中 CYP24 基因的减少和延迟表达得到证明。
相似文献
1
1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.1α,25-二羟维生素 D3-3β-溴代醋酸酯，一种有潜力的癌症治疗药物：合成与作用机制。
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2537-40. doi: 10.1016/j.bmcl.2011.02.025. Epub 2011 Feb 18.
2
Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid.利用产生大鼠线粒体CYP24的重组大肠杆菌细胞进行的代谢研究表明，CYP24可将1α,25-二羟基维生素D3转化为钙三醇酸。
Eur J Biochem. 1999 May;262(1):43-8. doi: 10.1046/j.1432-1327.1999.00375.x.
3
QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells.QW-1624F2-2，一种1,25-二羟基维生素D3的合成类似物，增强了对其他类维生素A的反应，并抑制了人转移性乳腺癌细胞的侵袭性。
Mol Cancer Ther. 2006 Nov;5(11):2806-14. doi: 10.1158/1535-7163.MCT-06-0092.
4
1alpha,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) hydroxylates the carbon at the end of the side chain (C-26) of the C-24-fluorinated analog of 1alpha,25-dihydroxyvitamin D3.1α,25-二羟基维生素D3-24-羟化酶（CYP24）使1α,25-二羟基维生素D3的C-24氟化类似物侧链末端（C-26）的碳原子发生羟基化。
J Biol Chem. 1997 May 30;272(22):14115-9. doi: 10.1074/jbc.272.22.14115.
5
Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.在 19-去甲-1α,25-二羟基维生素 D3 的碳 2 位用 3-羟丙基取代，生成一种类似物，在 PC-3 前列腺癌细胞中具有增强的化疗效力。
J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):269-75. doi: 10.1016/j.jsbmb.2011.08.010. Epub 2011 Sep 3.
6
Antagonistic action of novel 1alpha,25-dihydroxyvitamin D(3)-26, 23-lactone analogs on 25-hydroxyvitamin-D(3)-24-hydroxylase gene expression induced by 1alpha,25-dihydroxy-vitamin D(3) in human promyelocytic leukemia (HL-60) cells.新型1α,25-二羟基维生素D(3)-26,23-内酯类似物对1α,25-二羟基维生素D(3)诱导的人早幼粒细胞白血病（HL-60）细胞中25-羟基维生素D(3)-24-羟化酶基因表达的拮抗作用。
Arch Biochem Biophys. 2000 Aug 1;380(1):92-102. doi: 10.1006/abbi.2000.1902.
7
Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation.激素1α,25-二羟基维生素D3的非钙调节、抗增殖、具有转录活性的24-氟代杂合类似物。合成及初步生物学评价。
J Med Chem. 1998 Jul 30;41(16):3008-14. doi: 10.1021/jm980031t.
8
Antagonistic action of novel 1alpha,25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1alpha,25-dihydroxyvitamin D3.新型1α,25 - 二羟基维生素D3 - 26,23 - 内酯类似物对1α,25 - 二羟基维生素D3诱导的人白血病细胞（HL - 60）分化的拮抗作用
J Biol Chem. 1999 Jun 4;274(23):16392-9. doi: 10.1074/jbc.274.23.16392.
9
Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).与1α,25-二羟基维生素D₃相比，评估维生素D受体的共价修饰剂1α,25-二羟基维生素D₃-3-溴乙酸酯对人角质形成细胞增殖抑制增强作用的机制研究。
Arch Biochem Biophys. 1999 Oct 1;370(1):34-44. doi: 10.1006/abbi.1999.1353.
10
Metabolism of 26,26,26,27,27,27-F6-1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats.CYP24对26,26,26,27,27,27-F6-1α,25-二羟基维生素D3的代谢：人和大鼠基于物种的差异。
Biochem Pharmacol. 2003 Jun 15;65(12):1957-65. doi: 10.1016/s0006-2952(03)00190-4.
引用本文的文献
1
VDX-111 targets proliferative pathways in canine cancer cell lines.VDX-111 靶向犬科癌细胞系中的增殖途径。
PLoS One. 2024 May 21;19(5):e0303470. doi: 10.1371/journal.pone.0303470. eCollection 2024.
2
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.致癌磷酸酶PRL-3的缺失促进了一个介导三阴性乳腺癌生长的TNF-R1反馈环。
Oncogenesis. 2016 Aug 15;5(8):e255. doi: 10.1038/oncsis.2016.50.
3
PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.泌乳素-3（PRL-3）在三阴性乳腺癌细胞中激活粘着斑通路，以改变对细胞迁移和侵袭至关重要的肌动蛋白结构和底物粘附特性。
Cancer Lett. 2016 Oct 1;380(2):505-512. doi: 10.1016/j.canlet.2016.07.017. Epub 2016 Jul 21.
4
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.使用抗癌药物AMPI-109进行全基因组功能遗传筛选，确定PRL-3是三阴性乳腺癌的致癌驱动因子。
Oncotarget. 2016 Mar 29;7(13):15757-71. doi: 10.18632/oncotarget.7462.
本文引用的文献
1
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.1α,25-二羟维生素 D3 的维生素 D 受体烷化衍生物抑制人肾癌细胞的生长并抑制肿瘤生长。
Cancer Prev Res (Phila). 2010 Dec;3(12):1596-607. doi: 10.1158/1940-6207.CAPR-10-0122.
2
3
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.一项关于静脉注射骨化三醇联合口服地塞米松和吉非替尼治疗晚期实体瘤患者的I期和药代动力学研究。
Cancer Chemother Pharmacol. 2009 Dec;65(1):33-40. doi: 10.1007/s00280-009-1000-2. Epub 2009 Apr 26.
4
Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications.使用在母体配体的三个不同位置含有交联探针的亲和标记试剂对核维生素D受体进行共价标记：结构和生化意义。
Bioorg Chem. 2009 Apr;37(2):57-63. doi: 10.1016/j.bioorg.2009.01.001. Epub 2009 Feb 14.
5
Vitamin D: a D-Lightful health perspective.维生素D：一个充满希望的健康视角。
Nutr Rev. 2008 Oct;66(10 Suppl 2):S182-94. doi: 10.1111/j.1753-4887.2008.00104.x.
6
Vitamin D and human health: lessons from vitamin D receptor null mice.维生素D与人类健康：维生素D受体基因敲除小鼠的启示
Endocr Rev. 2008 Oct;29(6):726-76. doi: 10.1210/er.2008-0004. Epub 2008 Aug 11.
7
Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma.3-溴乙酰氧基骨化二醇在高危神经母细胞瘤中的抗增殖和促凋亡特性
Chem Biol Drug Des. 2007 Oct;70(4):302-10. doi: 10.1111/j.1747-0285.2007.00567.x.
8
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.癌症中的维生素D信号通路：抗癌治疗的潜力
Nat Rev Cancer. 2007 Sep;7(9):684-700. doi: 10.1038/nrc2196.
9
Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells.一种25-羟基维生素D3衍生物在前列腺癌细胞中的作用机制及药效学研究。
Biochem Biophys Res Commun. 2007 Sep 14;361(1):189-95. doi: 10.1016/j.bbrc.2007.07.012. Epub 2007 Jul 16.
10
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.一项关于静脉注射骨化三醇联合口服吉非替尼用于晚期实体瘤患者的I期药代动力学和药效学研究。
Clin Cancer Res. 2007 Feb 15;13(4):1216-23. doi: 10.1158/1078-0432.CCR-06-1165.
Zotero 插件